Next Investors logo grey

CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough

|

Published 06-FEB-2020 09:50 A.M.

|

5 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone.

In an important technological breakthrough that will expand its cannaQIX® human health product line, Creso has developed its first water-soluble micro-granulated hemp plant granules product.

Developed in conjunction with Switzerland’s Domaco Pharma, the new technology allows hemp oil-free manufacturing of cannaQIX® hemp plant-based gum arabicum lozenges – Creso’s hemp and vitamin-based food supplement.

Just a week ago, Creso announced it had sold over 2.5 million cannaQIX® lozenges (the equivalent of 100,000 pack sold) since the product’s launch in April 2018.

Today’s news should be the catalyst to further increase those numbers in human health products and complement the innovations Creso is also making in animal health.

For those just catching up on the story this year, Creso’s started 2020 with a bang reaching an estimated 100,000 dogs, equating to over three million anibidiol® sachets of its pet complementary feed doses sold since that product’s launch in late-2017.

We are only a month and a week into the new year, but already Creso has taken huge strides in the development of its human and animal health products.

So, let’s look in more detail at its latest news and what this means for its product growth.

Checking in on ...

Next Investors Image

Share Price: $0.15

Market capitalisation: $26.1 million

Here’s why I like Creso Pharma:

Screen Shot 2020-02-06 at 9.49.24 am

A quick recap

Creso Pharma (ASX:CPH) has had one of its busiest starts to the year for some time, achieving three major milestones only six weeks into 2020.

It began the year by announcing its animal health hemp derived product anibidiol® had reached an estimated 100,000 dogs, which brings the total number of anibidiol® sachets doses sold to over three million since the products launch in late-2017.

Read: CPH Delivers Over 3 Million Anibidiol Doses to Europe's Dogs

Creso backed this news up by reaching another impressive figure: 100,000 cannaQIX® human health products sold – that equates to over 2.5 million lozenges sold.

Read: CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone

As you may have read in the previous article, January’s positive news resulted in Creso’s share price increasing by more than 70% from about 11 cents per share at the start of the month to a high of 19 cents.

The company has come back a little to 15 cents, however with today’s news and plenty more catalysts to come, it shouldn’t be too long before it heads north again.

The latest milestone

Developed over the past nine months, the new technology developed by Creso in conjunction with Switzerland’s Domaco Pharma, will provide a major benefit to natural hemp plant consumers.

Domaco pharma is a division within the Domaco Group and specialises in high quality products with active pharmaceutical ingredients and therapeutic plants.

Creso and Domaco have a long standing relationship. The pair has been working together since 2017, when CPH negotiated at the start a binding Letter of Intent (LOI) with the Swiss based food and pharma development company which saw them work together on the development, manufacture and commercialisation of CPH’s human and animal health hemp derived products.

You can read more about its initial relationship in the following Finfeed article:

domaco FF

The relationship is now much stronger, with the latest technology developed by Creso and Domaco leading to its first water-soluble micro-granulated hemp plant granules product.

The new technology allows hemp oil-free manufacturing of cannaQIX® hemp plant-based gum arabicum lozenges – Creso’s hemp and vitamin-based food supplement.

“We are proud of having successfully developed this innovative oil free hemp plant based technology,” said CPH CEO Miri Halperin Wernli.

The hemp compounds within the products are already approved for use in consumer products, which means Creso now has an additional path to market for its hemp-based food supplements without the need for regulatory approval.

This gives Creso significant regulatory advantages in several countries. So, not only does this development expand the product line, it increases the company’s commercial options and expands the potential territories it can sell these products in.

The new products use natural hemp plant and provide an “entourage effect” in which various compounds work together to strengthen the key benefits such as helping to manage stress and improving well-being.

Creso Pharma plans to distribute the new products globally with different commercial partners in several countries and expects that the products will be ready for launch in Q3 2020.

Cannabis products increasingly used for stress management

There is some way to go and many studies to be done before cannabis and hemp products are widely accepted as help for stress and anxiety. However, positive steps have been taken in reassuring the public that genuine, legal, regulatory products are a viable alternative.

The following video released by the world renowned Mayo Clinic gives insight into how medical marijuana is being used to treat pain and disease, specifically epilepsy.

Use of medicinal-based cannabis treatments is becoming more commonplace.

Creso is looking to put itself at the forefront of product development in a legal market set to be worth US$66.3 billion (A$98.6B) by the end of 2025.

Yet, Creso’s advantage is that it is not only working to support the lives of humans in the management of pain and anxiety, but animals as well.

Given its impressive start to the year, Creso is certainly one company in this space that investors should keep an eye on, especially as it looks to roll out more products during the year.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.